fentaNYL 2750 mcg/55 mL (50 mcg/mL) in prefilled syringe, COMPOUNDED DRUG, For Institutional or...
FDA Drug Recall #D-1554-2014 — Class II — June 27, 2014
Recall Summary
| Recall Number | D-1554-2014 |
| Classification | Class II — Moderate risk |
| Date Initiated | June 27, 2014 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Healix Infusion Therapy, Inc. |
| Location | Sugar Land, TX |
| Product Type | Drugs |
| Quantity | 220 syringes |
Product Description
fentaNYL 2750 mcg/55 mL (50 mcg/mL) in prefilled syringe, COMPOUNDED DRUG, For Institutional or Office Use Only--Not for Resale Federal Law Prohibits Dispensing without Prescription Healix Infusion Therapy, Inc. (866) 298-4826 1075 West Park One Drive, Suite 200, Sugar Land, Texas, 77478 NDC 75901-8008-33
Reason for Recall
Lack of Assurance of Sterility: Firm received fentanyl from a supplier who recalled it because fliptop vial crimps were loose or missing.
Distribution Pattern
Texas and Georgia
Lot / Code Information
Lots 7083-0, 7202-0, 7222-0 Exp. 08/14
Other Recalls from Healix Infusion Therapy, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1555-2014 | Class II | fentaNYL 5000 mcg/250 mL (20 mcg/mL) in 0.9% So... | Jun 27, 2014 |
| D-1551-2014 | Class II | fentaNYL 1500 mcg/30 mL (50 mcg/mL) in prefille... | Jun 27, 2014 |
| D-1552-2014 | Class II | fentaNYL 2500 mcg/250 mL (10 mcg/mL) in 0.9% So... | Jun 27, 2014 |
| D-1553-2014 | Class II | fentaNYL 200 mcg/100 mL (2 mcg/mL) and Ropivaca... | Jun 27, 2014 |
| D-1422-2014 | Class II | BUPivacaine HCl 0.25% Preservative Free (2.5 mg... | Feb 13, 2014 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.